By Chris Wack
Apellis Pharmaceuticals shares were up 14% to $36.40 in premarket trading after the company said it saw positive data from its extension study following 30 months of continuous treatment with Syfovre pegcetacoplan injection.
Syfovre is the first and only FDA-approved treatment for geographic atrophy secondary to age-related macular degeneration.
The data, which reinforce the long-term efficacy and safety of Syfovre, demonstrated "robust and increasing effects" through 30 months with both monthly and every-other-month treatment. The data showed that Syfovre reduced GA lesion growth by up to 45% in patients with nonsubfoveal lesions.
The safety profile of Syfovre in the study continued to be consistent with previously reported Phase 3 data. Between months 24 and 30, zero non-serious adverse events of ischemic optic neuropathy were reported in either treatment group, and one serious adverse event was reported in the monthly group.
Write to Chris Wack at chris.wack@wsj.com
